Date: 2015-03-17
Type of information: Nomination
Compound:
Company: Polyphor (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 17, 2015, Polyphor , a privately held Swiss pharmaceutical company specializing in the discovery and development of macrocycle drugs, announced the appointment of Michael Altorfer as new CEO and successor of Jean-Pierre Obrecht as of March 31, 2015. Jean-Pierre Obrecht will continue to support the company in his role as a Member of the Board of Directors. Michael Altorfer joined Polyphor in 2001. He has served Polyphor in various functions, first as Head of the Small Molecule Service Business, then as Chief Financial Officer and Head of Corporate Development, and was Chief Operating Officer since 2014. Michael Altorfer started his career as a scientist in pharmaceutical research at Sandoz, Ciba-Geigy (Summit, NJ, USA), and Roche. From 1996 to 2001 he held program management and line management roles at the investment bank UBS Warburg. Michael Altorfer studied Natural Sciences at the Swiss Federal Institute of Technology (ETH) in Zurich, with the main focus on chemistry, toxicology, and immunology. He obtained his Ph.D. in Chemistry in 1996 under the supervision of Prof. Dr. H.-J. Hansen (University of Zurich) and Prof. Dr. K. Müller (Roche) and an MBA degree from the University of Rochester, NY, USA. The company also announced that it recently appointed Leon Hooftman, M.D., as Chief Medical Officer and Adesh Kaul as Head Corporate Development to complement Polyphor’s executive management team. Leon Hooftman, M.D., Chief Medical Officer (CMO). He is an accomplished pharmaceutical physician with more than 20 years of experience in pharmaceutical drug development in the areas of immunology, haematology and oncology, and has several New Drug Applications to his credit. Before joining Polyphor Dr. Hooftman was CMO of Synthon BV. Previously he was CMO at Chroma Therapeutics Ltd, where he moved after having been Head of Clinical Development at Celltech. Prior to that he was Clinical Science Director Oncology and Immunology in global drug development at Roche for several years. Dr. Hooftman holds an M.D. and B.Sc. in medical sciences of Utrecht University and is a registered medical practitioner in the UK and the Netherlands. Adesh Kaul has extensive experience in the area of corporate- and business development in the Pharma and Biotech industry. Since 2009 he worked at Basilea Pharmaceutica AG, from 2010 as Head Business Development & Investor Relations, from 2009 to 2010 as Head Public Relations & Corporate Communications. In previous positions Mr. Kaul was Senior Financial Analyst at Neue Züricher Bank; and held several senior executive positions in general management and sales & marketing at Genedata AG. Adesh Kaul holds master degrees both in biochemistry (1998) and economics (2001) from the University of Basel, and he received an Executive MBA from HSG St. Gallen in 2006.
Financial terms:
Latest news:
